Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quince Therapeutics ( (QNCX) ) has shared an update.
On April 22, 2026, Quince Therapeutics increased the size of its board of directors to four members and appointed June Bray as an independent Class I director, effective immediately, to serve until the 2026 annual meeting of stockholders. Bray, who has no disclosed family or material transactional ties to the company, was also named to the Nominating & Governance, Audit, and Compensation committees, and will receive standard cash retainers under the company’s outside director compensation policy without an accompanying stock option grant.
Under this policy, Bray is entitled to a $38,000 annual retainer for board service, plus additional annual retainers of $7,500, $5,500, and $4,000 for her roles on the Nominating & Governance, Audit, and Compensation committees, respectively. She will also enter into Quince’s standard indemnification agreement for directors, reinforcing the company’s governance framework as it adds experienced independent oversight to its board and key committees.
The most recent analyst rating on (QNCX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.
Spark’s Take on QNCX Stock
According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.
The score is primarily constrained by very weak financial performance (pre-revenue, widening losses, accelerating cash burn, and negative equity), indicating high financing and dilution risk. Technicals remain fragile with negative MACD and longer-term downtrend signals, only modestly offset by near-oversold readings. Corporate events add significant listing-compliance and strategic-uncertainty risk despite the positive step of settling the EIB debt.
To see Spark’s full report on QNCX stock, click here.
More about Quince Therapeutics
Quince Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of therapeutic products, with its shares listed on the Nasdaq Stock Market. The company is governed by a board of directors that includes independent members who serve on key committees overseeing governance, audit, and executive compensation matters.
Average Trading Volume: 10,591,531
Technical Sentiment Signal: Sell
Current Market Cap: $20.7M
For a thorough assessment of QNCX stock, go to TipRanks’ Stock Analysis page.